2020
DOI: 10.1016/j.neuropharm.2020.108225
|View full text |Cite
|
Sign up to set email alerts
|

Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
9
0
1

Year Published

2021
2021
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 194 publications
1
9
0
1
Order By: Relevance
“…One important caveat regarding the Taiwan study is that in this population, areca is used without tobacco, whereas in countries like India and Myanmar, areca is normally combined with substantial amounts of tobacco, 13 so that in those populations, nicotine dependence is likely to be coincident with betel quid use. For such populations of betel quid users, perhaps a better approach would be to use the alternative antidepressant bupropion, 52 which has the additional indication as a smoking cessation aid.…”
Section: Discussionmentioning
confidence: 99%
“…One important caveat regarding the Taiwan study is that in this population, areca is used without tobacco, whereas in countries like India and Myanmar, areca is normally combined with substantial amounts of tobacco, 13 so that in those populations, nicotine dependence is likely to be coincident with betel quid use. For such populations of betel quid users, perhaps a better approach would be to use the alternative antidepressant bupropion, 52 which has the additional indication as a smoking cessation aid.…”
Section: Discussionmentioning
confidence: 99%
“…In this area we observed a statistically significant improvement, increasing the percentage of the correct answer to 53.3% among people after our educational intervention (p = 0.048). Currently, seven smoking cessation therapies are approved by the United States Food and Drug Administration (FDA), including two drugs: varenicline, bupropion [10]. As presented by Sabat et al, lifestyle modification, including weight reduction and cessation of smoking, are crucial in HS management and the practitioners should present patients with possible therapeutic options that may help them in achieving their therapeutic goals [1].…”
Section: Discussionmentioning
confidence: 99%
“…Some studies have targeted the norepinephrine system to explore treatments for nicotine addiction or overweight. Bupropion, a smoking‐cessation drug approved by the United States Food and Drug Administration, 49 inhibits smoking behavior by inhibiting the dopamine transporter and the norepinephrine transporter, and the nicotinic acetylcholine receptors 41,50 . Moreover, appetite suppressant amphetamine, which has a molecular structure similar to bupropion, works by inhibiting NA release from synaptic vesicles and extracellular NA reuptake by NAT in synaptic clefts 47 .…”
Section: Discussionmentioning
confidence: 99%
“…Bupropion, a smoking-cessation drug approved by the United States Food and Drug Administration, 49 inhibits smoking behavior by inhibiting the dopamine transporter and the norepinephrine transporter, and the nicotinic acetylcholine receptors. 41,50 Moreover, appetite suppressant amphetamine, which has a molecular structure similar to bupropion, works by inhibiting NA release from synaptic vesicles and extracellular NA reuptake by NAT in synaptic clefts. 47 Future research could investigate whether bupropion can reduce food consumption/ suppress appetite to treat overweight through the NA system.…”
Section: Association Between Ina Components and Neurotransmitter Acti...mentioning
confidence: 99%